Afri Grow has secured an exclusive distribution agreement with Gamma Diagnostics for the African market. The company has obtained regulatory approval for the import and distribution of its GPF tests from the South African Health Products Regulatory Authority (SAHPRA).
It plans to introduce cutting-edge medical diagnostics technology into Africa, including a CE-marked ELISA assay that can detect micro-clotting and inflammation at an early stage.
Afri Grow has engaged the best cold chain logistics and clearing agents to streamline the “source-to-sale” logistical chain for
successful delivery of tests to customers.
The company will continually invest in research and development to stay at the forefront of the rapidly evolving medical diagnostics industry.
The GammaCoeur™
GammaCoeur™ is a semi-automated quantitative ELISA method for the detection and assessment of Gamma Prime Fibrinogen (GPF) in human venous plasma samples for use in clinical and research laboratories.
GPF Testing enables earlier and accurate detection of a patient’s risk of clotting, thus improving treatment options, patient outcomes and survival. GammaCoeur™ is intended to be used as part of a risk assessment in adults suspected of/at risk for cardiovascular disease (CVD), for example, adults with hypertension, increased BMI, diabetes, history of smoking, or family history of CVD. It is a semi-automated quantitative ELISA method for the detection and assessment of GPF in human venous plasma samples for use in clinical and research laboratories.
Principle of the Test
The GammaCoeur™ assay is a two-site sandwich immunoassay that measures the gamma-prime fibrinogen isoform in human plasma samples. Gamma-prime fibrinogen in the sample binds to a monoclonal capture antibody coated on the assay plate microwells.
After incubation, excess sample (including unbound non-gamma-prime fibrinogen [i.e., gammaA/gammaA fibrinogen] and other plasma components) are removed by washing. Enzyme-labeled polyclonal anti-fibrinogen detection antibody is added, which binds to the captured gamma-prime fibrinogen, forming a “capture antibody/analyte/detection antibody” sandwich. After another incubation, excess detection antibody is removed by washing.
Finally, a substrate for the enzyme-labeled detector is added to generate a colored product. After a last incubation, a stop solution is added to each well and the absorbance of the colored end-product is read on a spectrophotometer. The amount of colored reaction product formed is proportional to the amount of enzyme-labeled antibody bound to analyte, which is in turn proportional to the amount of gamma-prime fibrinogen present in the sample. All reagents required are provided in the GammaCoeur™ Test Kit.
Our Team
Dr. Grant Nicholas
Dr.Johan Badenhorst
Basson Piek
Adriaan du Plessis
